ClinicalTrials.gg
RecruitingNCT07469787BOOST-RUpdated Apr 21, 2026

Compassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology

An observational study in Chronic Inflammatory Rheumatic Diseases of Childhood, Juvenile-Onset Chronic Inflammatory Rheumatic Diseases and Transition of Care in Chronic Inflammatory Rheumatic Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Rheumatic Diseases with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Rheumatic Diseases · France.

Planned enrollment
15th of 15
50 · median 397
Started
2026
with 1 other
Observational
15 of 25
5 open now
Registered
25th of 25
by date
Lead sponsor
4 of 25
Assistance Publique - Hôpitaux de Paris

Among the 25 studies in Rheumatic Diseases with a site in France, this one is the 15th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2026, is one of 15 observational ones, and was the 25th registered.

Rheumatic Diseases

264 studies on the registry are indexed under Rheumatic Diseases; 60 are open to participants now.

Browse Rheumatic Diseases studies →

Open to participants now

8 of the 25 studies in Rheumatic Diseases with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Rheumatic Diseases studies recruiting now, 18 (44%) set no upper age limit and 12 (29%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Rheumatic Diseases with a site in France, or all of them as a file.
02

Study summary

The transition from pediatric to adult care is a critical period for young people with chronic inflammatory rheumatic diseases (CIRD) and is associated with risks of poor self-management, loss to follow-up, and disease worsening. Although structured transition programs have been recommended, real-world data on their effectiveness in rheumatology remain limited.

Since 2018, a structured transition program has been implemented at Bicêtre University Hospital (AP-HP, France), combining early transition preparation, a therapeutic patient education (TPE) workshop, and a joint pediatric-adult transition consultation. Some patients benefit from both components, while others receive a transition consultation only.

The BOOST-R study is a monocentric, non-interventional observational study designed to evaluate the impact of different transition modalities on self-management after transfer to adult care. The primary objective is to compare transition readiness, assessed using the validated French version of the Transition Readiness Assessment Questionnaire (TRAQ-FR), between patients who received a TPE workshop plus a transition consultation and those who received a transition consultation only.

Secondary objectives include evaluating continuity of care after transition, identifying factors associated with successful transition, assessing the contribution of the RESRIP support network, and describing patients who did not benefit from structured transition support.

Read the detailed description

The transition from pediatric to adult healthcare services represents a vulnerable period for adolescents and young adults with chronic inflammatory rheumatic diseases (CIRD). This phase is associated with increased risks of poor treatment adherence, disruption of follow-up, and adverse disease outcomes. While structured transition programs have been shown to improve patient autonomy and continuity of care, evidence in rheumatology remains limited, particularly regarding real-life effectiveness after transfer to adult care.

At Bicêtre University Hospital (AP-HP, France), a structured transition program has been progressively implemented since 2018 in collaboration with adult rheumatology and internal medicine departments. This program includes early transition information, progressive empowerment, a therapeutic patient education (TPE) workshop (MIRAJE program), and a joint pediatric-adult transition consultation. In parallel, some patients benefit from additional educational and administrative support provided by the RESRIP network after transition.

The BOOST-R study is a monocentric, observational, non-interventional study conducted in the pediatric rheumatology department of Bicêtre University Hospital. Adult patients with a diagnosis of CIRD who were followed in pediatric rheumatology and participated in a joint pediatric-adult transition consultation between 2018 and 2024 are eligible. Patients are contacted by postal mail and invited to complete an online questionnaire after receiving study information and having the opportunity to express non-opposition.

The primary outcome is transition readiness assessed using the French validated 20-item Transition Readiness Assessment Questionnaire (TRAQ-FR). The primary analysis compares the mean total TRAQ-FR score between patients who benefited from a TPE workshop plus a transition consultation and those who received a transition consultation only. Higher TRAQ-FR scores indicate better self-management and readiness for adult care.

Secondary outcomes include indicators of continuity of care after transition, such as number of adult care visits, delay to first adult visit, treatment adherence, and disease flares. Additional analyses will explore demographic, clinical, social, and educational factors associated with successful transition, evaluate the impact of support by the RESRIP network, and describe patients who did not benefit from structured transition interventions.

Statistical analyses will include descriptive analyses and multivariable regression models adjusted for relevant confounders, including age, sex, underlying disease, socio-professional status, and time since transition. Sensitivity analyses using propensity score methods will be performed to account for the non-randomized design.

The study involves no intervention and no additional risk for participants. Data are collected and managed in accordance with applicable French and European data protection regulations.

03

Conditions studied

  • Chronic Inflammatory Rheumatic Diseases of Childhood
  • Juvenile-Onset Chronic Inflammatory Rheumatic Diseases
  • Transition of Care in Chronic Inflammatory Rheumatic Diseases

Browse trials for

Keywords

  • Continuity of care
  • Therapeutic patient education
  • Self-management
  • Transitional care
  • Pediatric to adult transition
  • Chronic inflammatory rheumatic diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Young adults with a diagnosis of chronic inflammatory rheumatic disease previously followed in pediatric rheumatology, who transitioned to adult care after participating in a joint pediatric-adult transition consultation at Bicêtre Hospital between 2018 and 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of chronic inflammatory rheumatic disease
  • Previously followed in pediatric rheumatology at Bicêtre Hospital
  • Participation in a joint pediatric-adult transition consultation between 2018 and 2024
  • Affiliated with a health insurance system
  • No objection expressed to participation after being informed about the study

Exclusion criteria

Exclusion Criteria:

  • Patient lost to follow-up
  • No participation in a joint pediatric-adult transition consultation
  • Patient under guardianship, curatorship, or legal protection
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Total Score

    Total score of the Transition Readiness Assessment Questionnaire - French version (TRAQ-FR). The TRAQ-FR is a validated self-administered questionnaire assessing transition readiness in adolescents and young adults with chronic disease. It includes 20 items rated on a 5-point Likert scale (1-5). The total score is calculated as the mean of completed items. Score range: 1 to 5. Higher scores indicate greater transition readiness (better outcome).

    Time frame: Baseline (at the time of questionnaire completion in 2026, corresponding to 1 to 8 years after transition depending on individual transition date)

Secondary outcomes

  1. Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Domain Scores

    Domain-specific scores of the TRAQ-FR, including: Medication management, Appointment keeping, Tracking health issues, Communication with healthcare providers, Managing daily activities, Each domain score is calculated as the mean of completed items within that domain. Score range for each domain: 1 to 5. Higher scores indicate greater transition readiness.

    Time frame: Baseline (at the time of questionnaire completion in 2026)

  2. Continuity of adult care within 12 months after transition

    Proportion of patients who attended at least one adult specialist consultation within 12 months after their last pediatric visit. Unit of measure: Percentage (%). Higher percentage indicates better continuity of care.

    Time frame: 12 months after transition

  3. TRAQ-FR Total Score according to participation in structured transition support programs

    Comparison of TRAQ-FR total score between patients who participated in a structured transition support program (therapeutic patient education and/or structured support network) and those who did not. Score range: 1 to 5. Higher scores indicate greater transition readiness.

    Time frame: Baseline (at the time of questionnaire completion in 2026)

  4. Continuity of adult care according to participation in structured transition support programs

    Proportion of patients attending at least one adult specialist consultation within 12 months after transition, compared between patients with and without structured transition support. Unit of measure: Percentage (%).

    Time frame: 12 months after transition

  5. Successful transition defined by TRAQ-FR total score ≥4

    Proportion of patients with a TRAQ-FR total score ≥4, considered indicative of high transition readiness. Unit of measure: Percentage (%). Higher percentage indicates more successful transition.

    Time frame: Baseline (at the time of questionnaire completion in 2026)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.

Of 37 observational studies under Rheumatic Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 14. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Mar 13, 2026
StartActual
Feb 26, 2026
Primary completionEst.
Aug 26, 2027
CompletionEst.
Aug 26, 2027
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07469787
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Feb 26, 2026
Primary completion
Aug 26, 2027 (estimated)
Completion
Aug 26, 2027 (estimated)
Last update
Apr 21, 2026

Study contacts

Perrine DUSSER, MD PhD
Contact
perrine.dusser@aphp.fr
145213146 ext. 0033

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion